Key Points
- 1. Hipra is joining a European project aiming to reduce the vaccine development time to 100 days.
- 2. The project, called SPEEDCELL, aims to rapidly develop biological products against new pandemics.
- 3. The initiative plans to reduce dependence on third countries by increasing Europe's crisis response capacity.
By the Numbers
1. Development time of up to 100 days
Spanish biotechnology company Hipra is joining a European project that aims to reduce the development time of vaccines and other biological products to just 100 days in the event of new pandemics or health emergencies. This initiative, called SPEEDCELL, aims to strengthen the continent's response capacity during potential crisis periods.
The strategy of the Girona-based company also aims to reduce Europe's dependence on external sources for vaccine supply. Thus, in future global health crises, the region is planned to quickly produce its own solutions without having to rely on manufacturers in third countries.
React to this story
Ask about this story
Answers are AI-generated from this story only.
Frequently Asked Questions
- 1. S: What is the main purpose of the SPEEDCELL project?
- C: This project aims to reduce the development time of vaccines and other biological products to just 100 days in new pandemics.
- 2. S: What is Hipra's main motivation for joining this initiative?
- C: The company aims to strengthen Europe's capacity to respond to health crises and reduce the continent's dependence on manufacturers in third countries.
- 3. S: Which region and sector does the SPEEDCELL project cover?
- C: This initiative, which involves the Girona-based Hipra, covers the field of pandemic preparedness and biotechnology across Europe.
This is an AI-generated summary. The full story lives at the source.
Read the full story at the sourcediaridegirona.catHow we produce our content →Related stories
Economy